Rhythm Pharmaceuticals Inc (RYTM)

Currency in USD
102.74
-2.15(-2.05%)
Closed·
102.740.00(0.00%)
·

RYTM Financial Summary

Key Ratios

P/E Ratio-32.82
Price/Book73.98
Debt / Equity50.52%
Return on Equity-117.04%
Dividend Yield0.00%
EBITDA-190.68M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
2025
31/12
* In Millions of USD (except for per share items)

Analyst Ratings

15 Buy
2 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 140.19
(+36.45% Upside)

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
-0.73 / -0.81
Revenue / Forecast
71.26M / 67.53M
EPS Revisions
Last 90 days

FAQ

What were Rhythm Pharma's earnings for the latest quarter?

The Rhythm Pharma EPS (TTM) is -3.12. Rhythm Pharma reported sales of 71.26, net income of -49.30, and EPS of -0.73 for the latest quarter.

What was Rhythm Pharma's net income for the latest quarter?

Rhythm Pharma's net income for the latest quarter was -49.30.

How did Rhythm Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 60.11 million USD in the previous quarter to 71.26 million USD in the latest quarter, and net income moved from -55.64 million USD to -49.30 million USD compared to the previous quarter.

What is Rhythm Pharma's net profit margin on a TTM basis?

Rhythm Pharma's trailing twelve months (TTM) net profit margin is -85.59%.

How does Rhythm Pharma's debt to equity ratio compare to industry standards?

Rhythm Pharma's total debt-to-equity ratio is 50.52%.

What is Rhythm Pharma's return on investment on a TTM basis?

Rhythm Pharma's trailing twelve months (TTM) return on investment (ROI) is -117.04%.

How has Rhythm Pharma's total revenue grown this year?

Rhythm Pharma's total revenue was 60.11 million USD in the previous quarter and 71.26 million USD in the latest quarter.

What is Rhythm Pharma's gross margin on a TTM basis?

Rhythm Pharma's trailing twelve months (TTM) gross margin is 89.00%%.

What was Rhythm Pharma's revenue per share for the latest quarter?

Rhythm Pharma's revenue per share for the latest quarter was 49.88.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.